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TLR3 agonists induce fibronectin 
aggregation by activated 
astrocytes: a role of pro-
inflammatory cytokines and 
fibronectin splice variants
Inge Werkman1,2, Arend H. Sikkema1,2, Joris B. Versluijs1, Jing Qin1, Pascal de Boer1 & 
Wia Baron  1*
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system which 
eventually results in axonal loss mainly due to failure of remyelination. Previously we have shown 
that the persistent presence of stable astrocyte-derived fibronectin aggregates in MS lesions impairs 
OPC differentiation, and thereby remyelination. Here we set out to discern whether and, if so, how 
inflammatory mediators as present in MS lesions trigger astrocytes to form fibronectin aggregates. 
Our findings revealed that in slice cultures only upon demyelination, the TLR3 agonist Poly(I:C) evoked 
astrocytes to form fibronectin aggregates. Consistently, pro-inflammatory cytokine-pretreated 
astrocytes were more susceptible to Poly(I:C)-induced fibronectin aggregation, indicating that 
astrocytes form fibronectin aggregates upon a double hit by inflammatory mediators. The underlying 
mechanism involves disrupted fibronectin fibrillogenesis at the cell surface as a result of a cytokine-
induced increase in relative mRNA levels of EIIIApos-Fn over EIIIBpos-Fn and a Poly(I:C)-mediated decrease 
in integrin affinity. Remarkably, fibronectin aggregation is exacerbated by white matter astrocytes 
compared to grey matter astrocytes, which may be a reflection of higher expression levels of EIIIApos-
fibronectin in white matter astrocytes. Hence, interfering with alternative fibronectin splicing and/or 
TLR3-mediated signaling may prevent fibronectin aggregation and overcome remyelination failure in 
MS lesions.
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by demyelination, 
inflammation and neurodegeneration in grey matter (gm) and white matter (wm)1. In the early stages of MS, 
remyelination restores axonal support and saltatory nerve conduction2, while upon disease progression remyeli-
nation often fails, resulting in permanent axonal loss and disease progression1,3,4. Studies in rodent models showed 
that efficient remyelination requires recruitment of oligodendrocyte progenitor cells (OPCs) into the lesion area, 
followed by differentiation into myelin-producing mature oligodendrocytes3,5–7. In parallel, an orchestrated 
inflammatory response is initiated to remove remyelination-inhibiting myelin debris, ultimately resulting in a 
local microenvironment that favors the differentiation of recruited OPCs3,8. Remarkably, remyelination is more 
efficient in gm lesions than in wm lesions9–12, emphasizing an important role of the local cellular and molecular 
environment in remyelination efficiency.
CNS demyelination is accompanied by activation of astrocytes and microglia and the release of a myriad 
of pro-inflammatory cytokines, immuno-regulatory factors and extracellular matrix (ECM) molecules1,3,5,13. 
ECM remodeling plays a significant role in the remyelination process. For example, the transient upregulation of 
fibronectin in demyelinated areas is beneficial for OPC recruitment, i.e., the early stages of remyelination, while its 
timely removal is required to allow OPC differentiation to proceed14–16. Reactive astrocytes are the primary source 
of the transiently deposited fibronectin upon demyelination15,17. In chronic demyelinated MS lesions and in lesions 
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of an experimental model for MS, i.e., chronic relapsing experimental autoimmune encephalomyelitis (crEAE), 
fibronectin is not cleared and remains present in the form of stable aggregates15. As dimeric fibronectin18–21, 
fibronectin aggregates efficiently block myelin formation in vitro as well as remyelination in vivo15,22. Strikingly, 
while multimeric fibronectin is detected upon cuprizone-induced demyelination, fibronectin aggregates are not 
formed upon prolonged expression of fibronectin and demyelination14. Similarly, fibronectin aggregates are not 
observed in lysolecithin-induced demyelination experimental models and slice cultures15,22. Hence, fibronectin 
aggregates are not formed upon demyelination by default.
The fibronectin molecule contains a multitude of variable regions generated by alternative splicing of a sin-
gle gene, including domains EIIIA (EDA in human) and EIIIB (EDB in human) that are specific for cellular 
fibronectin and which may have various functions23,24. For example, inclusion of either domain alters the con-
formation of fibronectin, thereby interfering with its integrin and cell binding properties25–29. Organization of 
fibronectin is affected by several processes, including assembly into fibronectin fibrils, proteolytic turnover, and 
biochemical crosslinking and restructuring. Recently, we have shown that tissue transglutaminase 2 (TG2), when 
exogenously supplied, can cross-link astrocyte-deposited fibronectin on a laminin substrate30. However, endog-
enously expressed TG2 does not contribute to astrocyte-mediated fibronectin aggregation, while being involved 
in fibronectin fibril formation30. In addition, proteomic analysis revealed that TG2 is not present in fibronectin 
aggregates31. Hence, the underlying mechanism of fibronectin aggregation by astrocytes is not yet known.
MS lesions contain more inflammatory mediators derived from infiltrated peripheral cells than toxin-induced 
lesions. For example, the pro-inflammatory cytokines IL1β, IFNγ and TNFα32–34 and endogenous Toll-like 
receptor (TLR) agonists35–38 are abundantly present in MS lesions. In addition, TLRs are upregulated within MS 
lesions and present on activated astrocytes39. As astrocyte activity is induced in a context-dependent manner and 
regulated by, among others, pro-inflammatory cytokines and TLR-mediated signaling events39–43, fibronectin 
aggregate formation may be evoked by local inflammatory mediators. Here, we aimed to clarify whether and how 
immune-modulating factors, known to be present in MS lesions, trigger astrocytes to produce stable fibronectin 
aggregates. Our findings indicate that astrocytes form fibronectin aggregates by a double hit mechanism that 
involves activation of astrocytes by a demyelinating event and/or exposure to pro-inflammatory cytokines via 
a mechanism that involves a cytokine-mediated alteration in the expression of fibronectin splice variants and a 
Poly(I:C)-induced decrease in fibronectin binding by astrocytes. In addition, while wm astrocytes and gm astro-
cytes were similar responsive to Poly(I:C), wm astrocytes formed more fibronectin aggregates than gm astrocytes 
in vitro. This may reflect the more prominent presence of fibronectin aggregates and the decreased remyelination 
capability in wm compared to gm MS lesions.
Results
TLR3 agonists induce extracellular fibronectin aggregate formation by astrocytes in vitro. 
Previously, we have shown that fibronectin aggregates are formed at the relapse phase in crEAE, but not in 
toxin-induced models14,15, indicating that inflammation may contribute to fibronectin aggregation. To assess 
whether inflammatory mediators that are abundantly present in MS lesions contribute to fibronectin aggregation, 
we applied a reductionist approach and exposed primary rat astrocytes to pro-inflammatory cytokines IL1β, IFNγ 
and TNFα, and TLR2, TLR3, and TLR4 agonists zymosan, Poly(I:C) and LPS, respectively. Previous characteri-
zation of fibronectin aggregates indicated their insolubility in the ionic detergent sodium deoxycholate (DOC), 
while remaining in the stacking gel of SDS-PAGE gels15,22,44. Accordingly, after a 48-hour incubation with the 
inflammatory cytokines, extracellular deposits were extracted in DOC buffer and the extent of fibronectin aggre-
gation was assessed by Western blot. Exposure to the TLR3 agonist and viral dsRNA mimetic Poly(I:C) signifi-
cantly induced fibronectin aggregate formation (Fig. 1a,b, ins Fn, Wilcoxon Signed Rank Test p < 0.001, n = 16). 
Also, exposure to LPS, a bacterial membrane component that activates TLR4, reproducibly enhanced fibronectin 
aggregation, although to a lesser extent than Poly(I:C) (Fig. 1a,b, ins Fn, Wilcoxon Signed Rank Test p = 0.016, 
n = 7). In contrast, fibronectin aggregation was unchanged upon exposure to the TLR2 agonist zymosan and 
the pro-inflammatory cytokines IL1β, IFNγ and TNFα (Fig. 1a,b, ins Fn). Total cellular fibronectin expression 
was similar at all conditions (Fig. 1a,c, lysates). For all treatments, GFAP expression was increased compared to 
untreated astrocytes (Fig. 1a), indicating that astrocytes were activated. In addition, expression of iNOS, known 
to be differentially upregulated in astrocytes in response to inflammatory mediators45, was uncorrelated with the 
extent of fibronectin aggregation (Fig. 1a). Thus, Poly(I:C) induced-fibronectin aggregation is not a reflection of 
enhanced astrocyte activation. Exposure to the endogenous TLR3-agonist protein stathmin also increased the 
amount of DOC-insoluble fibronectin aggregates in deposits compared to untreated astrocytes (Fig. 1d,e, stath-
min p = 0.017, n = 5), while no significant alterations in overall fibronectin expression were detected (Fig. 1d,f). 
The more selective TLR3 agonist Poly(A:U) also reproducibly, but not significantly, increased aggregation of 
fibronectin (Fig. 1d,e, Poly(A:U) p = 0.114, ns, n = 3). Hence, our findings indicate that TLR3 agonists, and to a 
lesser extent a TLR4 agonist, induced extracellular fibronectin aggregate formation by astrocytes.
TLR3 agonist Poly(I:C) decreases astrocyte adhesion to fibronectin. In most cell types, fibronectin 
is assembled into a fibrillar matrix. This process initiates at the cell surface primarily via binding to integrin α5β1, 
and is supported by binding to integrin αvβ323,46–50. Upon exposure to Poly(I:C), i.e., at fibronectin aggregating 
conditions, fibronectin assembled at the cell surface of astrocytes in a clustered manner, forming large, elongated 
structures (Fig. 2a). In contrast, untreated astrocytes showed a more diffuse staining and smaller, punctuated 
structures of fibronectin at the cell surface (Fig. 2a,b, small p = 0.006, n = 3; large p = 0.048, n = 3). Moreover, 
Poly(I:C) reduced the adhesion of astrocytes to fibronectin in the presence of Mn2+, a known enhancer of inte-
grin affinity51 (Fig. 2c, Poly(I:C) + Mn2+ versus Mn2+ p = 0.011, n = 3). This indicates that Poly(I:C) interfered 
with binding of fibronectin to integrins, its main receptors at the cell surface. An adhesion assay in the presence 
of integrin-specific blocking antibodies showed that astrocytes primarily adhered to fibronectin via integrin β1 
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(Fig. 2d, β1 p = 0.006, n = 4). Selective blocking of integrin β3 and integrin β5 did not significantly affect adhe-
sion of astrocytes to fibronectin (Fig. 2d). Cell surface biotinylation of untreated and Poly(I:C)-treated astrocytes, 
followed by immunoprecipitation of integrin β1, β3 or β5 and visualization of surface integrins by Western blot-
ting and streptavidin detection revealed that surface expression of integrin β1, β3 and β5 was virtually similar 
in untreated and Poly(I:C)-treated cells (Fig. 2e,f). Hence, Poly(I:C) interfered not with the cell surface levels of 
integrin β1, β3 and β5, but rather modulated integrin affinity that may result in more localized and large fibril-like 
structures at the cell surface.
White matter astrocytes generate more fibronectin aggregates than grey matter astrocytes. 
Fibronectin aggregates have been examined in wm MS lesions15, while the above experiments were performed with 
cortical, i.e., gm-derived, astrocytes. Given the reported functional differences between gm and wm astrocytes52–54, 
we next examined whether wm astrocytes also form fibronectin aggregates in response to TLR3 agonist Poly(I:C). 
Fibronectin aggregation was enhanced by approximately 2-fold upon Poly(I:C) exposure in both wm and gm astro-
cytes (Fig. 3a,b, wm + Poly(I:C), Wilcoxon Signed Rank Test p < 0.001, n = 12; gm + Poly(I:C) versus gm untreated, 
Mann Whitney test p = 0.012, n = 11), while cellular fibronectin levels were comparable (Fig. 3a,c). Intriguingly, wm 
astrocytes generated twice as much fibronectin aggregates than their gm counterparts (Fig. 3a,b, Wilcoxon Signed 
Rank Test p = 0.001, n = 11). As the cellular EIIIA- and EIIIB-fibronectin splice variants have been implicated in 
fibronectin fibril formation at the cell surface25–29, we next examined the expression levels of these splice variants 
in gm and wm astrocytes. Western blot analysis revealed that in vitro gm astrocytes expressed a lower proportion 
of EIIIApos-fibronectin than wm astrocytes (Fig. 3d,e gm p = 0.013, n = 4). Unfortunately, no suitable antibody to 
detect fibronectin that contains EIIIB is available. Hence, these findings showed that wm astrocytes generated more 
fibronectin aggregates than gm astrocytes, which may relate to elevated levels of EIIIApos-fibronectin in wm astro-
cytes, while the susceptibility of either astrocyte to Poly(I:C)-induced fibronectin aggregation was similar.
Poly(I:C) induces fibronectin aggregation only after demyelination in ex vivo organotypic cer-
ebellar slice cultures. To more closely mimic demyelination conditions, we next examined whether TLR3 
agonist Poly(I:C) also induces fibronectin aggregation in ex vivo organotypic cerebellar slice cultures. To prevent 
Figure 1. TLR3 agonists induce extracellular fibronectin aggregate formation by astrocytes. Western blot 
analysis of fibronectin (Fn) in DOC-soluble (sol, fibronectin dimers) and DOC-insoluble (ins, fibronectin 
aggregates) extracellular deposits (a,b,d,e) and Fn, GFAP and iNOS in total cell lysates (a,c,d,f) of primary 
rat astrocytes treated for 48 hours with pro-inflammatory cytokines IFNγ (500 units/mL), IL1β (10 ng/mL) 
or TNFα (10 ng/mL), or with TLR2 agonists zymosan (zym, 10 μg/mL), TLR3 agonists Poly(I:C) (50 μg/mL), 
Poly(A:U) (50 μg/mL), stathmin (0.5 μg/mL) and TLR4 agonist LPS (200 ng/mL). Representative blots of 3–16 
independent experiments are shown in (a,d) quantification of DOC-insoluble fibronectin aggregates in deposits 
in b,e, and quantification of fibronectin in total cell lysates in (c,f). Actin serves as a loading control for cell 
lysates; equal amounts of protein (12 μg) are subjected to DOC-(in)solubility analysis. Note that TLR3 agonists, 
and to a lesser extent TLR4 agonist LPS, induce fibronectin aggregation (Poly(I:C) p < 0.001; Poly(A:U) 
p = 0.114, ns; stathmin p = 0.018, LPS p = 0.016). Bars represent mean relative to their respective untreated 
control (ctrl), which was set at 1 in each independent experiment (horizontal line). Error bars show the standard 
error of the mean. Statistical analyses were performed using a Wilcoxon Signed Rank Test (Poly(I:C) and LPS 
in (a), failed Shapiro-Wilk normality test) or a one-sample t-test to test for differences between treatments and 
their respective control (*p < 0.05, **p < 0.01).
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that Poly(I:C) interferes with the initial events of demyelination, myelinated organotypic cerebellar slice cultures 
were first subjected to lysolecithin-induced demyelination and allowed to recover for 2 days. The demyelinated 
slice cultures were subsequently exposed to Poly(I:C) for another 2 days (Fig. 4a). Western blot analysis demon-
strated that sequential treatment with lysolecithin and Poly(I:C) significantly increased fibronectin aggregation 
compared to control and lysolecithin-treated cerebellar slice cultures (Fig. 4b,c, lysolecithin + Poly(I:C) p = 0.003, 
n = 8). Poly(I:C) treatment of myelinated cultures, thus without prior demyelination, did not result in increased 
fibronectin aggregation (Fig. 4b,c). Total levels of fibronectin were not significantly altered (Fig. 4b,d). Notably, 
while the expression of a major myelin-specific protein myelin basic protein (MBP) was decreased upon lysolec-
ithin treatment, MBP expression levels in Poly(I:C)-treated myelinated cerebellar slice cultures were similar to 
MBP levels in untreated myelinated cerebellar slice cultures (Fig. 4b). This indicates that transient exposure to 
Poly(I:C) alone did not induce demyelination. Expression of neuron-specific class III beta-tubulin, a neuronal 
marker recognized by the TuJ1 antibody, was unaffected in all conditions (Fig. 4b). In this slice culture model, 
spontaneous remyelination is observed approximately three weeks after lysolecithin-induced demyelination22,24,55. 
To assess whether Poly(I:C)-induced fibronectin aggregation interfered with OPC maturation, as observed upon 
intralesional injection of fibronectin aggregates in toxin-induced demyelinated lesions in vivo15,22, the extent of 
OPC maturation was determined at 21 days post lysolecithin (DPL)-induced demyelination (Fig. 4a). Western 
blot analysis revealed that MBP levels in lysolecithin-treated cerebellar slice cultures almost returned to the 
levels of untreated slice cultures (Fig. 4e,f). In contrast, MBP expression in lysolecithin and Poly(I:C)-treated 
Figure 2. Poly(I:C) induces formation of large elongated-structures of fibronectin at the cell surface, and 
decreases cell adhesion to fibronectin. (a,b) Fibronectin (Fn) immunocytochemistry of living primary rat 
astrocytes treated with Poly(I:C) (50 μg/mL) for 48 hours. Representative images of 4 independent experiments 
are shown in (a) quantification of cells with scattered small fibronectin structures and cells with large elongated 
fibronectin structures at the cell surface in (b). Note that Poly(I:C) decreases the amount of scattered fibronectin 
(p = 0.006) and increases the amount of fibril-like fibronectin (p = 0.048) at the cell surface. (c) Adhesion assay of 
astrocytes to fibronectin (n = 3). Primary rat astrocytes were left untreated or treated with Poly(I:C) (50 μg/mL) 
for 2 hours, in the absence or presence of Mn2+ (1 mM), known to increase integrin affinity. Note that Poly(I:C) 
decreases astrocyte adhesion to fibronectin even in the presence of Mn2+ (p = 0.011). (d) Adhesion assay of 
astrocytes to fibronectin in the absence or presence of functional blocking antibodies against integrin β1, β3 or 
β5 (n = 3–4). Note that astrocytes primarily bind to fibronectin via integrin β1. (e,f) Western blot analysis of 
cell surface expression of integrin β1, β3 and β5 of primary rat astrocytes treated with Poly(I:C) (50 μg/mL) for 
48 hours. lysates; equal amounts of protein (100 μg) are subjected to immunoprecipitation. Representative blot 
of 7–8 independent experiments are shown in (e), quantification in (f). Bars represent means relative to their 
respective untreated control (ctrl), which was set at 1 for each independent experiment (horizontal line). Error 
bars show the standard error of the mean. Statistical analyses were performed using a one-sample t-test to test for 
differences between treatments and their respective controls (*p < 0.05, **p < 0.01). An unpaired t-test was used 
to test for differences in adhesion between untreated and Poly(I:C)-treated cells in the absence or presence of 
Mn2+ (#p < 0.05). Scale bar is 20 µm.
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cerebellar slice cultures remained significantly decreased (Fig. 4e,f, lysolecithin + Poly(I:C) p = 0.014, n = 6). 
Exposure of myelinated slice cultures to Poly(I:C) had no effect on MBP expression levels after 21 days (Fig. 4e,f). 
Double labelling of MBP with the axonal marker neurofilament (NF-H) revealed that addition of Poly(I:C) to 
lysolecithin-demyelinated cerebellar slice cultures significantly decreased the percentage of myelinated axons 
at 21 DPL compared to the percentage of myelinated axons in lysolecithin-treated slices (Fig. 4g,h, lysoleci-
thin + Poly(I:C) n = 3, versus lysolecithin n = 6, p = 0.047). Thus, exposure to Poly(I:C) induced fibronectin 
aggregation only after demyelination, which resulted in impaired MBP re-expression and remyelination. As these 
findings showed that in slice cultures only activated astrocytes were susceptible to Poly(I:C)-induced fibronectin 
aggregate formation, we next examined whether pre-incubation with pro-inflammatory cytokines makes astro-
cytes more prone to Poly(I:C)-induced fibronectin aggregation.
Pre-incubation with pro-inflammatory cytokine potentiates Poly(I:C)-induced fibronectin 
aggregation. To assess a putative role of cytokines in fibronectin aggregation, gm and wm astrocytes were 
pre-exposed to a mixture of pro-inflammatory cytokines IFNγ, IL1β and TNFα for 24 hours, followed by stim-
ulation with Poly(I:C) for 48 hours (Fig. 5a). Pre-incubation of gm astrocytes with pro-inflammatory cytokines 
increased the level of fibronectin aggregates generated upon Poly(I:C) treatment compared to untreated astrocytes 
(Fig. 5b,c, gm-control versus gm + cytokines + Poly(I:C) p = 0.005, n = 4). However, the amount of fibronectin 
aggregates generated upon cytokines + Poly(I:C) treatment by gm astrocytes were still considerably less than of 
Figure 3. White matter astrocytes generate more fibronectin aggregates than grey matter astrocytes. (a–c) 
Western blot analysis of fibronectin (Fn) in DOC-soluble (sol, fibronectin dimers) and DOC-insoluble (ins, 
fibronectin aggregates) extracellular deposits (a,b) and total cell lysates (a,c) of primary rat grey matter (gm) 
and white matter (wm) astrocytes treated with Poly(I:C) (50 μg/mL) for 48 hours. Representative blots of 11–12 
independent experiments are shown in (a), quantification of DOC-insoluble fibronectin aggregates in deposits 
in (b) and quantification of fibronectin in total cell lysates in (c). Actin serves as a loading control for total cell 
lysates; equal amounts of protein (12 μg) are subjected to DOC-(in)solubility analysis. Note that wm astrocytes 
generate a higher absolute amount of fibronectin aggregates than gm astrocytes (p = 0.001). (d,e) Western 
blot analysis of EIIIApos-fibronectin in total cell lysates of gm and wm astrocytes. Representative blots of 4 
independent experiments are shown in (d), quantification of EIIIApos-fibronectin of total fibronectin is shown 
in e. Note that wm astrocytes express more EIIIApos-fibronectin than gm astrocytes (p = 0.013). Bars represent 
mean relative to wm astrocyte control (ctrl), which was set at 1 for each independent experiment (horizontal 
line). Error bars show the standard error of the mean. Statistical analysis was performed using a one-sample 
t-test (*p < 0.05, ***p < 0.001) to test for differences between Poly(I:C) treated wm astrocytes and wm control 
astrocytes (wm ctrl), a Wilcoxon Signed Rank Test was used to test for differences with wm control, and an 
Mann Whitney test was used to test for differences between untreated and Poly(I:C)-treated gm astrocytes 
(wm + Poly(I:C), gm ctrl and gm + Poly(I:C) failed Shapiro-Wilk normality test) (#p < 0.05).
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Poly(I:C)-treated wm astrocytes that were not pre-exposed to cytokines (Fig. 5b,c). The extent of Poly(I:C)-induced 
fibronectin aggregation was similar for cytokine-treated and untreated wm astrocytes (Fig. 5b,c). Fibronectin 
aggregation was not enhanced upon treatment with a mixture of pro-inflammatory cytokines alone in either 
type of astrocyte (Fig. 5b,c), which is in line with exposure to the single cytokines (Fig. 1a,b). Notably, cytokine 
treatment appeared to decrease the total amount of deposited fibronectin (Fig. 5b). As Poly(I:C) treatment 
reduced the binding of gm astrocytes to fibronectin (Fig. 2), next was examined whether cytokines affect cell 
adhesion. Exposure to pro-inflammatory cytokines alone did not affect adhesion of gm and wm astrocytes to 
fibronectin, however, pre-incubation with cytokines followed by Poly(I:C) treatment resulted in a significant 
Figure 4. TLR3 agonist Poly(I:C) induces fibronectin aggregation in organotypic cerebellar slice cultures 
only after demyelination, and inhibits remyelination. (a) Schematic representation of treatments and 
analysis. Organotypic cerebellar slice cultures obtained from newborn rats were cultured for 3 weeks to allow 
for myelination. At day 0, demyelination was induced by lysolecithin. At 2 days post lysolecithin (DPL), 
demyelinated slices were left untreated or treated with the TLR3 agonist Poly(I:C) (50 μg/mL) for 48 hours after 
which slices were washed and new medium was added. Remyelination was allowed until 21 DPL. (b–f) Western 
blot analysis of fibronectin (Fn), MBP (myelin marker) and TuJ1 (neuronal marker) in demyelinated slices 
5 DPL (b-d) and remyelinated slices 21 DPL. (e,f) Representative blots of 3–8 independent experiments are 
shown in (b,e) and quantification in (c,d,f). Actin was used as a loading control. (g,h) Immunohistochemistry 
for myelin (MBP, green) and axons (neurofilament, NF-H, red) at 5 and 21 DPL. Representative images of 
3–6 independent experiments are shown in (g), quantification of the % myelinated axons in (h) relative to 5 
DPL control. Bars represent mean relative to untreated myelinated control (ctrl), which was set at 1 for each 
independent experiment (horizontal line). Error bars show the standard error of the mean. Statistical analyses 
were performed using a one-sample t-test to test for differences with control slices (*p < 0.05, **p < 0.01), and 
a one way ANOVA with a Šidák multiple comparisons post-test was used to test for differences in remyelination 
on 21 DPL between lysolecithin and lysolecithin + Poly(I:C)-treated slices (# p < 0.05). Scale bar is 50 µm.
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decrease in astrocyte adhesion to fibronectin of both wm and gm astrocytes (Fig. 5d wm + cytokines + Poly(I:C) 
p = 0.008; gm + cytokines + Poly(I:C) p = 0.022, n = 3), which was more prominent in the presence of 
Mn2+ (Fig. 5g, wm + cytokines + Poly(I:C) p = 0.048; gm + cytokines + Poly(I:C) p = 0.002, n = 3). Thus, 
pre-incubation with pro-inflammatory cytokines may enhance fibronectin aggregation by potentiating 
the negative effect of Poly(I:C) on astrocyte adhesion to fibronectin.
Figure 5. Pre-incubation with pro-inflammatory cytokines potentiates Poly(I:C)-induced fibronectin 
aggregation by grey matter astrocytes. (a) Schematic representation of astrocyte treatment and analysis. Primary 
rat grey matter (gm) and white matter (wm) astrocytes are pre-treated for 24 hours with a mixture of IFNγ (500 
units/mL), IL1β (10 ng/mL) and TNFα (10 ng/mL), followed by Poly(I:C) treatment (50 μg/mL) for 48 hours. 
(b,c) Western blot analysis of fibronectin (Fn) in DOC-soluble (sol, fibronectin dimers) and DOC-insoluble 
(ins, fibronectin aggregates) extracellular deposits. Representative blots of 3–4 independent experiments are 
shown in (b), quantification of DOC-insoluble aggregated fibronectin in c. Equal amounts of protein (12 μg) 
are subjected to DOC-(in)solubility analysis. Note that pre-incubation with cytokines potentiates fibronectin 
aggregation by gm (p = 0.004), but not wm astrocytes. (d,e) Adhesion assay of astrocytes to fibronectin (n = 3). 
Astrocytes were treated for 1 hour with a mixture of IFNγ (500 units/mL), IL1β (10 ng/mL) and TNFα (10 ng/
mL), followed by adhesion for 2 hours in the absence or presence of Poly(I:C) (50 μg/mL) and/or the absence 
(d) or presence (e) of Mn2+ (1 mM), which is known to increase integrin affinity. Note that pre-incubation with 
cytokines potentiates the decreased effect of Poly(I:C) on adhesion (wm + cytokines + Poly(I:C) p = 0.008; 
gm + cytokines + Poly(I:C) p = 0.022), which cannot be overcome by Mn2+ (wm + cytokines + Poly(I:C) 
p = 0.048; gm + cytokines + Poly(I:C) p = 0.002). Bars represent mean relative to wm astrocyte control (wm 
ctrl, c) or untreated control (ctrl, d,e), which was set at 1 for each independent experiment (horizontal line). 
Error bars show the standard error of the mean. Statistical analyses were performed using a one-sample t-test 
to test for differences with wm astrocyte control (ctrl, c) or their respective untreated control (d,e) (*p < 0.05, 
**p < 0.01, ***p < 0.001). A one way ANOVA with a Dunnett multiple comparison post-test was used to 
compare treatment groups with untreated gm control (c) (###p < 0.001) and a one way ANOVA with a Šidák 
multiple comparisons post-test was used to test for differences between treatment groups (d,e) (##p < 0.01).
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Pro-inflammatory cytokines enhance the EIIIApos- to EIIIBpos-Fn mRNA ratio. As an increased 
level of EIIIApos-fibronectin in wm astrocytes correlated with increased fibronectin aggregation (Fig. 3a,b,d,e), 
and EIIIApos-fibronectin is involved in cell adhesion25,26,28,29, the effect of pro-inflammatory cytokines on 
EIIIApos-fibronectin levels was examined next. Astrocytes were treated for 24 hours with pro-inflammatory 
cytokines, and cultured for another 24 hours (Fig. 6a). Exposure to pro-inflammatory cytokines reproducibly, 
but not significantly, increased the proportion of EIIIApos-fibronectin in wm astrocytes, but not in gm astro-
cytes (Fig. 6b,c, wm + cytokines p = 0.100, ns, n = 4), while total fibronectin levels substantially decreased 
upon cytokine treatment in wm astrocytes (Fig. 6b,d, wm + cytokines p = 0.125, ns, n = 4) and significantly 
decreased in gm astrocytes (Fig. 6b,d, gm + cytokines p = 0.046, n = 4). As to the best of our knowledge, an 
antibody for EIIIB that is suitable for Western blotting is not available, the mRNA expression of alternatively 
spliced EIIIApos-Fn and EIIIBpos-Fn was examined. To this end, a semi-quantitative RT-PCR using primers that 
span each of the alternatively spliced Fn exons was performed. Using this method, primer pairs produce two 
different products, i.e., a larger product when the alternatively spliced exon was included and a smaller product 
if it was spliced out (Fig. 6e). When normalized to total Fn mRNA levels, i.e., EIIIApos-Fn + EIIIAneg-Fn, a consid-
erable increase in EIIIApos-Fn mRNA levels was observed upon exposure to cytokines, alone or in combination 
with Poly(I:C) treatment in wm astrocytes (Fig. 6e,f, wm + cytokines p = 0.148, ns; wm + cytokines + Poly(I:C) 
p = 0.082, ns, n = 5), which is consistent with the substantial increase in protein expression shown by 
Western blot analysis (Fig. 6b,c). In contrast, the mRNA levels of EIIIBpos-Fn decreased in both wm and gm 
astrocytes upon cytokine pre-incubation and remained decreased following stimulation with Poly(I:C) 
(Fig. 6e,g, wm + cytokines p = 0.043, n = 4; wm + cytokines + Poly(I:C) p = 0.031, n = 4; gm + cytokines 
p = 0.003, n = 5; gm + cytokines + Poly(I:C) p = 0.094, ns, n = 5). This resulted in a significantly enhanced 
EIIIApos/EIIIBpos-Fn mRNA ratio in Poly(I:C)-stimulated cytokine-pretreated wm astrocytes, while the ratio 
was reproducibly increased in cytokine-treated wm astrocytes (Fig. 6e,h, wm + cytokines p = 0.104, ns, n = 4; 
wm + cytokines + Poly(I:C) p = 0.034, n = 4). A similar trend was observed with gm astrocytes (Fig. 6e,h, 
gm + cytokines p = 0.075, ns, n = 5, gm + cytokines + Poly(I:C) p = 0.102, ns, n = 5). The EIIIApos/EIIIBpos-Fn 
mRNA ratio moderately, but significantly, increased upon Poly(I:C) treatment alone in wm astrocytes (Fig. 6e,h, 
wm + Poly(I:C) p = 0.044, n = 4), which in contrast to pre-incubation with cytokines was not a result of decreased 
EIIIBpos-Fn. Thus, upon pre-incubation with cytokines of gm and wm astrocytes, and upon Poly(I:C) treatment of 
wm astrocytes, the relative mRNA levels of EIIIApos-Fn compared to the EIIIBpos-Fn mRNA levels were increased. 
As the cellular fibronectin molecule contains either the EIIIA or the EIIIB domain, or both combined, this indi-
cates there is a relative increase of fibronectin containing solely the EIIIA domain. To visualize fibronectin splice 
variants at the astrocyte surface and/or in extracellular aggregates, non-permeabilized cells were co-labelled with 
an antibody that recognizes fibronectin that lacks EIIIB and an antibody that recognizes total fibronectin. Upon 
pre-incubation with cytokines and subsequent exposure to Poly(I:C), thus at conditions where fibronectin aggre-
gates were generated (Fig. 5b,c), large extracellular structures located in between cells showed clear immunoreac-
tivity to both EIIIBneg-fibronectin and total fibronectin (Suppl. Fig. S1a,b, arrows), while EIIIBneg-fibronectin was 
hardly visible at the cell surface. Similar extracellular structures that were enriched for EIIIBneg-fibronectin were 
visible upon exposure to Poly(I:C) alone, but to a lesser extent than Poly(I:C)-treated cytokine-pre-incubated 
astrocytes. Thus, the extracellular fibronectin aggregates that were not attached to the cell surface likely contained 
fibronectin that lacks the EIIIB domain and/or may have underwent a conformational change that increased the 
accessibility for the anti-EIIIBneg-fibronectin antibody.
Enhanced EDApos-FN to EDBpos-FN mRNA ratio in cultured MS astrocytes. Our previous findings 
demonstrated that cultured wm astrocytes obtained from MS patients (MS astrocytes), but not wm astrocytes 
obtained from healthy subjects (control astrocytes), possessed the ability to form fibronectin aggregates with-
out prior exposure to cytokines and in the absence of Poly(I:C) treatment15. Given that an enhanced presence 
of EIIIApos fibronectin over EIIIBpos fibronectin correlated with fibronectin aggregation, the EDApos-fibronectin 
protein levels and EDApos/EDBpos-FN mRNA ratio in MS astrocytes were examined next. Western blot anal-
ysis revealed that with the exception of astrocytes obtained from one healthy subject, the proportion of 
EDApos-fibronectin of total fibronectin in MS astrocytes was substantially increased compared to control astro-
cytes (Fig. 7a,b, ctrl n = 5 versus MS p = 0.212, ns, n = 4). In addition, qPCR analysis showed that while the 
EDApos-FN mRNA levels over total Fn were virtually similar (Fig. 7c), EDBpos-FN mRNA levels were significantly 
decreased in MS astrocytes compared to control astrocytes (Fig. 7d, MS versus control p = 0.005, n = 6). As a 
consequence, the EDApos/EDBpos-FN mRNA ratio was higher in MS astrocytes than in control astrocytes (Fig. 7e, 
MS n = 5 versus control p = 0.015, n = 6). Thus, similar to pro-inflammatory cytokine-treated rat astrocytes, the 
relative EDBneg-FN mRNA levels were decreased in MS astrocytes compared to control astrocytes, indicating that 
as in primary rat astrocytes, an increase in EIIIApos/EIIIBpos-FN mRNA ratio correlated with enhanced fibronectin 
aggregation.
Discussion
Persistent ECM deposition in demyelinated MS lesions impedes remyelination15,16,56. This includes reactive astro-
cytes that form fibronectin aggregates which persist in MS lesions and impair OPC maturation15. Our present 
findings indicate that sequential activation of primary astrocytes by respectively a mixture of pro-inflammatory 
cytokines and TLR3 agonist Poly(I:C), increased fibronectin aggregation. Similarly, in organotypic cerebellar 
slice cultures, Poly(I:C) only induced fibronectin aggregation upon demyelination. Poly(I:C) treatment induced 
fibronectin aggregation to a similar extent by both primary gm and wm astrocytes, while wm astrocytes formed a 
higher absolute amount of fibronectin aggregates than gm astrocytes. Pro-inflammatory cytokines increased the 
relative mRNA levels of the alternatively spliced EIIIApos-Fn over EIIIBpos-Fn, which, together with subsequent 
Poly(I:C) exposure, decreased the binding of fibronectin to the surface of astrocytes. Consistently, fibronectin 
9Scientific RepoRtS |          (2020) 10:532  | https://doi.org/10.1038/s41598-019-57069-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
aggregate-forming MS astrocytes had a higher EDApos/EDBpos-Fn mRNA ratio than control astrocytes. Hence, 
both in vitro and ex vivo, fibronectin aggregates are formed by a double hit, i.e., first a pro-inflammatory 
cytokine-mediated activation of astrocytes followed by exposure to TLR3 agonists, which in vivo includes protein 
agonist stathmin57. This respectively interferes with alternative fibronectin splicing and fibronectin cell surface 
binding, making astrocytes more prone to form fibronectin aggregates.
Figure 6. Pro-inflammatory cytokines favor EIIIApos over EIIIBpos splicing in primary rat astrocytes. (a) 
Schematic representation of astrocyte treatment and analysis. Primary rat grey matter (gm) and white matter 
(wm) astrocytes were pre-incubated for 24 hours with a mixture of IFNγ (500 units/mL), IL1β (10 ng/mL)  
and TNFα (10 ng/mL), and left untreated or treated with Poly(I:C) (50 μg/mL) for 24 hours. (b–d) Western 
blot analysis of EIIIApos-fibronectin and total fibronectin in total cell lysates. Representative blots of 4 
independent experiments are shown in (b), quantification of EIIIApos-fibronectin of total fibronectin in (c) 
and total fibronectin in (d). Actin serves as a loading control. (e–h) RT-PCR analysis of EIIIApos-, EIIIAneg-, 
EIIIBpos- and EIIIBneg-Fn mRNA. Representative agarose gels of 4–5 independent experiments are shown 
in e, quantification of EIIIApos/total Fn, EIIIBpos/total Fn, and EIIIApos/EIIIBpos-Fn mRNA ratios in (f,g,h) 
respectively. Note that EIIIBpos-Fn mRNA, but not EIIIApos-Fn mRNA levels are decreased in cytokine 
pre-treated astrocytes (wm + cytokines p = 0.043; wm + cytokines + Poly(I:C) p = 0.031; gm + cytokines 
p = 0.003; gm + cytokines + Poly(I:C) p = 0.094, ns), resulting in an enhanced EIIIApos/EIIIBpos-Fn mRNA 
ratio (wm + cytokines p = 0.104, ns; wm + cytokines + Poly(I:C) p = 0.044; gm + cytokines p = 0.075, ns; 
gm + cytokines + Poly(I:C) p = 0.102, ns). Bars represent mean relative to their respective control astrocytes 
(ctrl), which was set at 1 for each independent experiment (horizontal line). Error bars show the standard error 
of the mean. Statistical analyses were performed using a one-sample t-test to test for differences with their 
respective control astrocytes (*p < 0.05, **p < 0.01).
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While fibronectin aggregates are not formed upon lysolecithin-induced demyelination in vivo15,22 and in cer-
ebellar slice cultures, Poly(I:C) treatment of demyelinated, but not myelinated, cerebellar slice cultures, induced 
fibronectin aggregation. Likely, in toxin-induced demyelinated lesions the activated astrocytes may not encoun-
ter a TLR3 agonist during the transient period of fibronectin deposition, and therefore do not form fibronec-
tin aggregates. In MS lesions, the prolonged presence of fibronectin as a consequence of a decreased ability to 
clear fibronectin by the lack of fibronectin (aggregate) clearing matrix metalloproteinases, such as MMP744, may 
increase the chance of encountering a TLR3 agonist as a double hit. In addition, due to inefficient removal of mye-
lin debris, activated astrocytes may encounter endogenous TLR3 protein agonist stathmin, an otherwise intra-
cellular myelin protein. Stathmin indeed induced fibronectin aggregate formation in vitro, is abundantly present 
in MS lesions, and mostly found in inflamed areas36,57. Moreover, TLR3 expression on the surface of astrocytes is 
enhanced39, and co-localizes with stathmin in MS lesions36,39,57. Notably, TLR3 recognizes dsRNA, and although 
some viruses are implicated in MS pathogenesis, these are mainly ssRNA viruses58, and thus it is not likely that 
these viruses are involved in fibronectin aggregation. Therefore, increased accessibility of the endogenous TLR3 
protein agonist stathmin in myelin debris combined with the prolonged presence of fibronectin, increases the 
change of a double hit, likely resulting in fibronectin aggregation in MS lesions. It remains however to be deter-
mined whether other cells in the cerebellar slice cultures may have contributed to fibronectin aggregation and/or 
remyelination failure, as microglia and oligodendrocytes also recognize Poly(I:C) via TLR359,60. Of relevance in 
this respect, Poly(I:C) did not induce fibronectin aggregation and/or demyelination in myelinated slice cultures.
Our present findings indicate that dysregulated fibronectin fibrillogenesis may underlie fibronectin aggre-
gation. In a cell-dependent manner, deposited fibronectin can be assembled into a branched, fibrillar network 
or matrix that plays an active role in providing environmental information to cells that encounter it, among 
others, by functioning as a scaffold for other bioactive signaling proteins61,62. Fibronectin matrix assembly is a 
complex multistep process, initiated upon binding of soluble dimeric fibronectin to activated cell surface integrin 
α5β1 (Fig. 8a) followed by unfolding, self-association of different fibronectin dimers and other ECM proteins 
into linear multimeric fibrils (Fig. 8b)46–48,50,63. Integrin αvβ3 also contributes to fibronectin fibrillogenesis23,49,64. 
Importantly, the binding strength of integrins to fibronectin is an essential part for the initiation and propaga-
tion of fibril formation. Both alternatively spliced domains EIIIA and EIIIB, although not essential, have been 
Figure 7. Increased EDApos-FN to EDBpos-FN mRNA ratio in MS astrocytes. Western blot analysis of total 
fibronectin and EDApos-fibronectin in total cell lysates (a,b) of control (5 healthy donors) and MS (4 MS donors) 
astrocytes cultures. Blot is shown in (a), quantification of EDApos-fibronectin of total fibronectin in (b). (c–e) 
qPCR analysis of EDApos/total FN (c), EDBpos/total FN (d), and EDApos/EDBpos-FN mRNA (e) ratios in control (6 
healthy donors) and MS (5 MS donors) astrocyte cultures. Note that the EIIIBpos-FN; mRNA levels of total FN 
mRNA levels are decreased in MS astrocytes (p = 0.0046), resulting in an enhanced EIIIApos-FN to EIIIBpos-FN 
mRNA ratio (p = 0.015). Bars represent means (c–e) or means relative to the average ratio of astrocytes obtained 
from postmortem tissue of healthy subjects, which was set at 1 (b). Error bars show the standard error of the 
mean. Statistical analyses were performed with a two-sided t-test to test for differences between control and MS 
astrocytes (b–e) (*p < 0.05, **p < 0.01).
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implicated in the level and stability of fibronectin fibril formation. More specifically, inclusion of the EIIIA domain 
enhances binding to integrin receptor α5β165, whereas EIIIB inclusion enhances cell adhesion to fibronectin via 
binding of integrin αvβ366,67. Thus, under normal circumstances, fibronectin binds to astrocytes via integrin 
α5β1, and likely also via integrin αvβ3, which supports the formation of fibronectin fibrils (Fig. 8a,b). Our data 
demonstrated that in pro-inflammatory cytokine-activated astrocytes, the relative EIIIApos-Fn over EIIIBpos-Fn 
mRNA levels were increased, which may strengthen the binding of fibronectin to integrin α5β1, and reduce 
binding to integrin αvβ3 (Fig. 8c). In addition, fibronectin without EIIIB is less able to make fibrils27, resulting in 
impartial refolding (Fig. 8c,d). Integrins transmit signals bi-directionally, i.e., via outside-in and inside-out sig-
naling68,69. The observed inability of Mn2+ to increase the integrin affinity of Poly(I:C)-treated astrocytes may be 
caused by a loss of inside-out activation of integrins upon exposure to Poly(I:C). This is consistent with a previous 
study that reports that Poly(I:C) decreases cell adhesion to fibronectin by a loss of inside-out signaling of active 
integrin β170. Thus, exposure to TLR3 agonist Poly(I:C) reduced the binding of astrocytes to fibronectin (Fig. 8d). 
Remarkably, pre-incubation with cytokines potentiated the Poly(I:C)-mediated loss of cell adhesion to fibronec-
tin, likely as fibronectin binding to the surface of cytokine-activated astrocytes rely more on integrin α5β1, due 
to a decrease in EIIIBpos-fibronectin27,65. In Poly(I:C)-treated cytokine-pre-incubated astrocytes, non-cell asso-
ciated fibronectin aggregates were visualized by an antibody that recognizes fibronectin that lacks EIIIB, while 
EIIIBneg-fibronectin was not recognized at the cell surface. Hence, as a consequence of Poly(I:C)-mediated loss of 
integrin affinity, the formed fibronectin fibrils may be released from the surface (Fig. 8d,1), refold and form aggre-
gates (Figs. 8d, 2). Indeed, unfolded non-cell associated fibronectin is prone to form aggregates71. Additionally, 
inclusion of EIIIB makes fibronectin more sensitive to proteolysis72, indicating that a slower degradation and pro-
longed presence of fibronectin due to the lack of EIIIB may increase the change of a double hit activation-induced 
Figure 8. Proposed model of fibronectin aggregation by astrocytes. (a,b) Schematic representation of 
fibronectin fibrillogenesis46–49,62,67. Under normal circumstances, fibronectin molecules bind primarily at the 
astrocyte surface to integrin α5β1, and to a lesser extent integrin αvβ3 (a). Fibronectin binding to the astrocyte 
surface unfolds fibronectin that allows self-association of fibronectin molecules to from a fibril matrix (b). (c,d) 
Schematic representation of fibronectin aggregation. Upon exposure to a pro-inflammatory environment, as 
present in MS lesions, relatively more EIIIA/EDApos-fibronectin than EIIIB/EDBpos-fibronectin is produced. (c) 
This results in enhanced binding to integrin α5β1, reduced binding to integrin αvβ3, and impartial unfolding 
of fibronectin. (c) Upon a second-hit with a TLR3 agonist, the binding of fibronectin to the astrocyte surface is 
reduced, resulting in detachment (1) and refolding (2) of the fibronectin multimers in aggregates. (d) Notably, 
when EIIIA/EDApos-fibronectin levels are already high, fibronectin aggregates may be formed without prior 
exposure to pro-inflammatory cytokines (b,d). (e) Description of the used elements and symbols.
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aggregate formation. Also, EIIIBneg-fibronectin in aggregates are more stable and less vulnerable to extracellular 
proteases72. Whether the detached fibronectin fibrils or multimers may act as seeds for further self-association of 
fibronectin and other ECM molecules and ultimately form aggregates remains to be determined.
Astrocytes adopt distinct phenotypes in response to their environment, and it should be taken into account 
that astrocyte responses to inflammatory mediators are regionally heterogeneous52,73. We show that Poly(I:C) 
treatment induced a 2-fold increase in fibronectin aggregation by both cultured gm and wm astrocytes, while 
also exposure to cytokines increased the EIIIApos/EIIIBpos-Fn mRNA in both gm and wm astrocytes. However, 
while the response to inflammatory mediators appeared similar, wm astrocytes formed a higher absolute 
amount of fibronectin aggregates than gm astrocytes. In fact, Poly(I:C)-treated wm astrocytes do not require 
a pre-incubation with cytokines to produce a maximum amount of aggregates in vitro. This may be partly due 
to the higher relative endogenous EIIIApos-fibronectin levels in wm astrocytes than in gm astrocytes, and that 
the maximum amount of fibronectin aggregates had been reached. Also, Poly(I:C) treatment without cytokine 
pre-incubation modestly favored EIIIApos-Fn over EIIIBpos-Fn splicing by wm astrocytes but not gm astrocytes. 
To what extent differences in regional fibronectin aggregation are responsible for the differences in remyelination 
capability in gm and wm MS lesions remains to be clarified. Cortical gm lesions occur without significant infil-
tration of haematogenous leukocytes and show less astrocyte reactivity compared to wm MS lesions74,75. This is 
primarily visible in type 1 leukocortical lesions. In these gm and wm spanning lesions, the gm area shows greater 
remyelination efficiency, which may be a reflection of lower astrocyte reactivity, higher number of cells of the 
oligodendrocyte lineage, regional heterogeneity of OPCs, and decreased intralesional ECM deposition10,12,76. The 
presence of fibronectin aggregates in gm MS lesions remains to be determined, but based on the less inflamma-
tory character of gm lesions75, the absence of fibronectin immunoreactivity in marmoset gm EAE lesions77 and 
our present findings, it is tempting to hypothesize that in gm MS lesions less remyelination-impairing fibronectin 
aggregates are formed than in (chronic) wm MS lesions.
Remarkably, postmortem-derived MS wm astrocytes form fibronectin aggregates in the absence of cytokines 
and TLR3 agonists15. MS astrocytes have been exposed to the pathological environment and have encountered 
pro-inflammatory cytokines that may have altered their fibronectin splicing as well as TLR3 agonists, which may 
explain their ability to form fibronectin aggregates in vitro in the absence of TLR3 agonists. Alternatively, an 
inherent difference in alternative fibronectin splicing between control and MS astrocytes, as for example observed 
for cultured gm and wm astrocytes, cannot be excluded. Following this reasoning, it would be interesting to 
examine whether control and MS gm astrocytes differ in alternative fibronectin splicing and aggregate formation. 
Intriguingly, as in cytokine-activated primary rat astrocytes, the EDApos/EDBpos-FN mRNA ratio was higher in MS 
astrocytes than in control astrocytes, as a consequence of reduced EDBpos-FN mRNA levels. Upon toxin-induced 
demyelination, astrocytes are also exposed to pro-inflammatory cytokines, while fibronectin aggregates are not 
detected in vivo14,15,22. Our previous findings revealed that FN mRNA levels, including EIIIApos- and EIIIBpos-FN 
transcripts, are increased in lysolecithin-induced demyelinated lesions at 5 DPL compared to unlesioned con-
trol15,16. Additional analysis of these data revealed that the mRNA ratio of EIIIApos/EIIIBpos-FN rather decreased 
than increased upon lysolecithin-induced demyelination compared to unlesioned controls at 5 DPL (0.52 ± 0.02, 
p = 0.01, n = 4), which is still evident at 14 DPL (0.57 ± 0.04, p = 0.046, n = 3), i.e., at remyelinating conditions. 
This may explain why astrocytes in lysolecithin-induced lesions are less susceptible to from fibronectin aggregates.
Taken together, we propose a double-hit model for fibronectin aggregation involving an initial activation 
in response to pro-inflammatory cytokines (first hit), which interferes with alternative fibronectin splicing, 
followed by a response to TLR3 agonists (second hit) that decreases integrin affinity (Fig. 8). Regional heter-
ogeneity is reflected by the increased amounts of fibronectin aggregates formed by wm astrocytes compared 
to gm astrocytes. Preventing fibronectin aggregate formation may prove beneficial as an approach for remyeli-
nation enhancing-based treatment of MS. Thus, factors that interfere with alternative fibronectin splicing and 
TLR3-mediated signaling, and/or factors that prevent the decreased fibronectin-integrin binding aid to proper 
fibril formation, thereby precluding aggregation, are potential targets to aid efficient remyelination in MS. As 
remyelination following demyelination is essential for axonal survival and restoration of saltatory conduc-
tion1–4, restoring remyelination in MS may be an effective treatment in halting disease progression and reversing 
disability.
Methods
Cell culture. Rat astrocytes. Animal protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Groningen. All methods were carried out in accordance with national and local 
experimental animal guidelines and regulations. Primary gm rat astrocytes of either sex were isolated from the 
neonatal cortex and wm astrocytes from neonatal non-cortical parts, which mainly consist of wm, by a shake 
off procedure and cultured as described19,59,76. Astrocytes were cultured at a density of 1 × 106 cells/10 cm-dish, 
50,000 cells/13-mm poly-L-lysine (5 µg/ml)-coated coverslip, or 20,000 cells/8-well Permanox chamber slide. 
When indicated, one hour after plating, cells were subjected to the inflammatory mediators IFNγ (500 units/mL), 
TNFα (10 ng/mL), IL1β (10 ng/mL), or TLR2 agonist zymosan (10 μg/mL), TLR3 agonist polyinosinic:polycy-
tidylic acid (Poly(I:C), 50 μg/mL), TLR3 agonist polyadenylic-polyuridylic acid (Poly(A:U), 50 μg/mL), TLR3 
agonist stathmin (0.5 μg/mL), or TLR4 agonist lipopolysaccharide (LPS, 200 ng/mL) for 48 hours.
Human astrocytes. Autopsy samples of human white matter brain material were obtained from the Netherlands 
Brain Bank. All donors from whom material was collected had signed written informed consent for brain autopsy 
and the use of material and clinical information for research purposes. All methods were carried out in accord-
ance with relevant guidelines and regulations. Control donors (5 female/1 male) were of ages between 63 and 94, 
and mean postmortem delay was 7.2 hours. MS donors (4 female/2 male) were of ages between 48 and 88, mean 
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postmortem delay was 7 hours, and mean disease duration was 29.3 years. Adult control and MS astrocytes were 
purified from post-mortem subcortical wm of non-demented healthy subjects and MS patients and cultured as 
described15,39.
Organotypic cerebellar slice cultures. Neonatal meninges-free rat cerebella of either sex were cut in 300 μm sag-
ittal sections and cultured in millicell cell culture inserts as described22,55. After 3 weeks, slices were left untreated 
or exposed to lysolecithin (0.5 mg/mL) for 17 hours to induce demyelination (day 0). At 2 days post lysolecithin 
(DPL) treatment, control and demyelinated slices were left untreated or exposed to Poly(I:C) (50 μg/mL) for 
48 hours. At 5 DPL, the tissue slices were either fixed in 4% paraformaldehyde (PFA) or homogenized in TE‐
buffer (10 mM Tris, 2 mM EDTA, pH 7.4) containing 0.25 M sucrose and a mix of protease inhibitors (Complete 
Mini) on ice, or left to examine remyelination until 21 DPL.
Biochemical analysis. Western blotting. Cells were lysed in TNE-lysis buffer containing 150 mM NaCl, 
50 mM Tris-HCl and 5 mM EDTA (pH 7.4) supplemented with 1% Triton X-100, and protease inhibitors. 
Extracellular deposits were obtained by lysing the cells in water for 2 hours at 37 °C and scraping the remain-
ing deposits in deoxycholate (DOC)-containing buffer (2% DOC, 2 mM EDTA, 5 mM Tris, pH 8.0). Following 
30 minutes of incubation in lysis buffer (cells) or DOC-buffer (deposits) on ice, protein concentrations were deter-
mined by a BioRad DC-protein assay using bovine serum albumin (BSA) as a standard. To separate DOC-soluble 
(fibronectin dimers) and -insoluble (fibronectin aggregates) proteins, equal amounts of protein of DOC-extracts 
were centrifuged at 16,000 g for 30 minutes at 16 °C. Samples were subjected to SDS-PAGE under reducing (cells, 
20 µg) or non-reducing conditions (deposits, 12 µg) to detect total fibronectin monomers or structural states of 
fibronectin, including aggregates and dimers, respectively. After transfer of the proteins to a PVDF membrane 
(Immobilon-FL) and blocking with 50% Odyssey blocking buffer in phosphate buffered saline (PBS) the mem-
branes were incubated overnight at 4 °C with the indicated primary antibodies (Suppl. Table S1). Appropriate 
secondary IRDye-conjugated antibodies were applied for 1 hour at room temperature followed by detection on 
the Odyssey Infrared Imaging system. Membrane washing between antibody incubations was performed with 
PBS supplemented with 0.05% Tween-20. Quantification was performed with FUJI ImageJ software.
Immunoprecipitation. Astrocytes were washed with ice-cold PBS and incubated in ice-cold sulfo-NHS-LC-biotin 
(0.1 mg/mL) for 1 hour on ice to biotinylate cell surface proteins. After three washes in cell wash buffer (65 mM 
Tris, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, pH 7.5), and two washes in PBS, the cells were scraped in TNE 
lysis buffer followed by sonication. Lysates (100 µg) were precleared by incubating lysates with rabbit Ig (rab-
bit gamma globulin 11.1 mg/mL), or mouse Ig (mouse gamma globulin 11.0 mg/mL), and 20 µl Protein A/G 
Plus-agarose beads for 1 hour at 4 °C. Precleared lysates were incubated overnight with anti-integrin antibodies 
(Suppl. Table S1) at 4 °C. Hamster-anti-β1 integrin was first linked to rabbit-anti-hamster for 30 minutes at room 
temperature. The samples were incubated with Protein A/G Plus-agarose beads for 3 hours at 4 °C. The beads were 
precipitated for 5 minutes, at 600 g, washed four times with immunoprecipitation wash buffer (cell wash buffer 
supplemented with 350 mM NaCl and 1% NP-40) and resuspended in non-reducing sample buffer. The samples 
were heated to 95 °C for 3 minutes, centrifuged for 5 minutes at 600 g, followed by Western blotting and detection 
of surface integrins using IR-dye-800-conjugated streptavidin.
Adhesion assay. Adhesion assays were performed as described78. For integrin blocking experiments, cells 
were incubated with the indicated anti-integrin antibodies for 30 minutes, at 37 °C. For cytokine pre-incubation 
experiments, cells were left untreated or pre-treated for 1 hour with cytokine mixture at 37 °C, followed by plating 
and stimulation with Poly(I:C) and/or MnCl2 (1 mM). Astrocytes were seeded at a density of 50,000 cells per well 
and left to adhere for 2 hours at 37 °C. Adhesion is expressed as percentage of the corresponding untreated cells 
or relative to MnCl2-treated cells.
Immunochemistry. Immunohistochemistry. Cerebellar slices were fixed for 1 hour in 4% PFA. After two 
washes with PBS the slices were blocked for 3 hours in Hanks Balanced Salt Solution supplemented with 1 mM 
HEPES, 10% heat inactivated normal goat serum, 2% heat inactivated horse serum, 1% BSA and 0.25% Triton 
X-100. Slices were incubated with the indicated primary antibodies in blocking solution for 48 hours at 4 °C 
(Table S1), washed three times in PBS supplemented with 0.05% Tween for 1 hour and incubated with appropri-
ate Alexa Fluor© secondary antibodies (1:500) overnight at 4 °C. After three washes the slices were mounted on 
glass slides using mounting medium to prevent image fading. Imaging were performed on a Leica TCS SP2 AOBS 
confocal microscope. The percentage of myelinated axons was calculated using MATLAB software as described22.
Immunocytochemistry. For live cell stainings, cells were blocked for 10 minutes with 4% BSA and incubated with 
anti-fibronectin antibodies (Suppl. Table S1) for 30 minutes on ice. After three washes in PBS, cells were incubated 
with the appropriate Alexa Fluor© secondary antibodies for 20 minutes on ice. Cells were fixed with 4% PFA and 
incubated with DAPI (1 μg/mL) for 15 minutes at room temperature. For staining of fixed cells, cells were first 
fixed sequentially with 2% and 4% PFA for 15 minutes each, and subjected to the indicated primary and second-
ary antibodies as described for live staining. Analysis and imaging were performed on a conventional Leica DMI 
6000 B immunofluorescence microscope. Astrocytes were scored based on their cellular surface extracellular 
fibronectin expression and subdivided into two categories, i.e., diffuse fibronectin staining in small, punctuated 
structures and fibronectin in large, elongated structures. Between 100–175 cells were counted per condition.
Polymerase chain reaction. Cells were scraped in RNA protect (Qiagen) and mRNA was isolated using 
an mRNA-isolation kit (Isolate II RNA Micro Kit; Bioline) according to manufacturer’s instructions. Total RNA 
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(1 μg) was reverse transcribed in the presence of oligo(dT)12–18 and dNTPs with M-MLV reverse transcriptase 
according to manufacturer’s instructions. Primer sequences are shown in Supplementary Table S2.
RT-PCR. cDNA was amplified using indicated primer sets and GoTaq Green Master Mix (Promega) accord-
ing to manufacturer’s instructions, and subjected to a 1.5% agarose gel. The EIIIA- and EIIIB-fibronectin prim-
ers generate two products: a band that includes the alternatively spliced domain (526 bp for EIIIApos-Fn, 640 bp 
for EIIIBpos-Fn) and another band when the respective domain is spliced out (256 bp for EIIIAneg-Fn, 367 bp for 
EIIIBneg-Fn79,80). Quantification was performed with FUJI ImageJ software. Relative expression of EIIIApos- and 
EIIIBpos-Fn is expressed as percentage of total Fn (positive and negative bands combined).
qPCR. Gene expression levels were measured by real-time quantitative RT-PCR using ABsolute QPCR SYBR 
Green Master Mix in a Step-One Plus Real-Time PCR machine. Measurements were performed in triplicate and 
amplification data was processed using LinRegPCR software81.
Statistics. Data are expressed as mean ± standard error of the mean (SEM) of at least three independent 
experiments. A Shapiro-Wilk normality test was first applied to test the normal distribution of the data. When 
normality failed, a Wilcoxon Signed Rank test or Mann Whitney test was used to test for statistical significance 
where indicated. When normality passed, statistical analysis was performed with a one-sample t-test when rela-
tive values of groups were compared with control by setting the untreated control values at 1 in each independent 
experiment. When values between two treatment groups were compared, statistical significance was assessed 
using a paired two-sided t-test or a one way ANOVA with a Šidák multiple comparisons post-test when compar-
ing more than two groups. When gm and wm astrocytes were compared, wm astrocyte control values were set at 
1. Here, statistical significance compared to wm control was performed using a one sample t-test (*), and a one 
way ANOVA with a Dunnett post-test was used to compare between gm samples and gm control (#). In case of 
human astrocyte cultures, arbitrary measured values were normalized to control values, with an arbitrary average 
control value of 1. Statistics were performed using GraphPad Prism 6.0. In all cases p-values of <0.05, <0.01, and 
<0.001 were considered significant and indicated with *, **, *** or #, ##, ###, respectively.
Data availability
All data generated during and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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